Edited by: Diego Cantoni, MRC-University of Glasgow Centre For Virus Research (MRC), United Kingdom
Reviewed by: Dhruv Desai, University of Pennsylvania, United States
*Correspondence: Ali Azizi,
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
The Coalition for Epidemic Preparedness Innovations (CEPI) established the Centralized Laboratory Network (CLN) in March 2020 in response to the SARS-CoV-2 pandemic. Initially, the network comprised a few high-quality laboratories located in North America, Europe, and Asia (
During the SARS-CoV-2 pandemic, the CLN played a crucial role by offering free testing of all samples for vaccine developers, regardless of their size, location and funding status (
After our significant contribution to controlling the SARS-CoV-2 pandemic, the CLN has expanded significantly, becoming the largest global network conducting global vaccine testing with 17 laboratories from 13 different countries announced so far. To date, five members of the CLN are in Low- and Middle-income Countries (LMICs) including Bangladesh, India, Kenya, Senegal, and Uganda, indicating an expansion in scale and geographical reach into the Global South. This expansion strengthens CEPI-CLN’s ability to standardize and accelerate the evaluation of vaccines against epidemic and pandemic diseases. By expanding into the Global South, the CLN reduces sample transfer and testing times, potentially accelerating vaccine development against emerging infectious diseases. In addition, we ensure that vaccine developers in each geographic region have access to the same level of resources. CEPI-CLN is poised to continue its vital role in accelerating the development of vaccines against emerging infectious diseases. Our network currently standardizes the assessment of vaccine efficacy against rare but potential diseases including Lassa, Nipah, Monkeypox, Sudan, Marburg, MERS, and others, ensuring uniformity and accelerating standardized assays for vaccines.
Looking ahead, CEPI remains committed to supporting vaccine developers. For funded CEPI developers, testing of samples will continue to be provided free of charge and for non-funded developers, CEPI will offer testing services at an affordable cost, ensuring that financial constraints do not hinder the progress of potential vaccine candidates. This commitment underscores CEPI’s mission to support global health by facilitating the development of vaccines against epidemic and pandemic diseases. In addition to providing free or affordable testing services, CEPI is committed to transparency and collaboration. All protocols and standard procedures within the CLN will be made accessible to anyone who requires them. This transparency not only fosters trust and collaboration within the scientific community but also ensures that best practices are shared and implemented across the network.
AA: Writing – original draft, Methodology, Supervision, Validation. VB: Writing – review & editing, Methodology, Supervision, Validation.
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CEPI.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.